A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
Member of the Expert Committee for the 2020 Antimicrobial Resistance Benchmark

Nina Grundmann

Nina Grundmann joined the IFPMA in June 2012. She leads IFPMA’s work on antimicrobial resistance and heads the secretariat of the AMR Industry Alliance, which represents more than 100 pharmaceutical companies. Nina has also worked on vaccine regulatory and programmatic policy and influenza vaccines.

Nina holds a master’s degree in International Affairs from the French Institute of Political Studies and a post-graduate degree in Risk Management from HEC Business School in Paris. Prior to joining IFPMA, Nina worked at Sanofi Pasteur on vaccination policy and advocacy and for the Mérieux Foundation to help enhance research capabilities in developing countries.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |